SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Kreuzberger, Nina; Hirsch, Caroline; Li Chai, Khai; Tomlinson, E.; Khosravi, Zahra; Popp, Maria; Neidhardt, Miriam; Piechotta, Vanessa; Salomon, Susanne; J Valk, Sarah; Monsef, Ina; Schmaderer, Christoph; M. Wood, Erica; So‐Osman, Cynthia; J. Roberts, David; McQuilten, Zoe; J Estcourt, Lise; Skoetz, Nicole

doi:10.1002/14651858.cd013825.pub2

Public

SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Published in Cochrane Database of Systematic Reviews • Sep 2, 2021

Authors:

Nina Kreuzberger

Caroline Hirsch

Khai Li Chai

Abstract

BACKGROUND: Monoclonal antibodies (mAbs) are laboratory-produced molecules derived from the B cells of an infected host. They are being investigated as a potential therapy for coronavirus disease 2019 (COVID-19). OBJECTIVES: To assess the effectiveness and safety of SARS-CoV-2-neutralising mAbs for ...

Subject

Coronavirus disease 2019 (COVID-19)

Virology

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!